Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Liabilities and Shareholders Equity (2018 - 2025)

Historic Liabilities and Shareholders Equity for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to $163.6 million.

  • X4 Pharmaceuticals' Liabilities and Shareholders Equity fell 820.03% to $163.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $545.2 million, marking a year-over-year decrease of 1589.49%. This contributed to the annual value of $146.4 million for FY2024, which is 55.07% down from last year.
  • Latest data reveals that X4 Pharmaceuticals reported Liabilities and Shareholders Equity of $163.6 million as of Q3 2025, which was down 820.03% from $105.2 million recorded in Q2 2025.
  • X4 Pharmaceuticals' 5-year Liabilities and Shareholders Equity high stood at $210.6 million for Q2 2024, and its period low was $81.0 million during Q2 2022.
  • Its 5-year average for Liabilities and Shareholders Equity is $139.7 million, with a median of $141.7 million in 2021.
  • In the last 5 years, X4 Pharmaceuticals' Liabilities and Shareholders Equity skyrocketed by 11402.26% in 2023 and then crashed by 5006.53% in 2025.
  • Quarter analysis of 5 years shows X4 Pharmaceuticals' Liabilities and Shareholders Equity stood at $117.2 million in 2021, then surged by 32.78% to $155.6 million in 2022, then dropped by 5.35% to $147.3 million in 2023, then dropped by 0.55% to $146.4 million in 2024, then grew by 11.68% to $163.6 million in 2025.
  • Its last three reported values are $163.6 million in Q3 2025, $105.2 million for Q2 2025, and $130.0 million during Q1 2025.